People: Cempra Inc (CEMP.W)

CEMP.W on CBOE When Trading NASDAQ Global Select Market

6.17USD
24 Apr 2013
Price Change (% chg)

$-0.15 (-2.37%)
Prev Close
$6.32
Open
$6.17
Day's High
$6.17
Day's Low
$6.17
Volume
100
Avg. Vol
2
52-wk High
$8.25
52-wk Low
$5.43

Search Stocks

Summary

Name Age Since Current Position

Garheng Kong

 2008 Independent Chairman of the Board

Prabhavathi Fernandes

 63 2005 President, Chief Executive Officer, Director

Mark Hahn

 50 2010 Chief Financial Officer, Executive Vice President

David Gill

 2012 Director

Dov Goldstein

 45 2008 Independent Director

John Johnson

 55 2009 Independent Director

Richard Kent

 62 2010 Independent Director

P. Sherrill Neff

 61 2011 Independent Director
» Insider Trading

Biographies

Name Description

Garheng Kong

 Dr. Garheng Kong, M.D., Ph.D., is Independent Chairman of the Board of Cempra, Inc. Prior to joining Sofinnova in 2010, Dr. Kong was a general partner with Intersouth Partners where he had board involvement with most of Intersouth's life science companies, including his role as Chairman of the Board of Directors for Cempra Pharmaceuticals Inc. Dr. Kong has full-cycle investing experience, sourcing, syndicating, managing and exiting investments. He also served as interim CEO for two Intersouth portfolio companies. Prior to Intersouth, he worked at GlaxoWellcome and McKinsey & Company. He received his M.D., Ph.D., in Biomedical Engineering, and M.B.A. from Duke University graduating at the top of his medical and business school classes. He also holds a B.S. in Chemical Engineering and a B.S. in Biological Sciences from Stanford University.

Prabhavathi Fernandes

 Dr. Prabhavathi B. Fernandes, Ph.D., is President, Chief Executive Officer, Director of Cempra Inc. Dr. Fernandes, one of founders, has been President and Chief Executive Officer and a member of board of directors since founding in November 2005. Prior to that, she was President and Chief Executive Officer of several privately-held companies, including DarPharma, Inc. from 2003 to 2005, Ricerca Biosciences from 2000 to 2003 and Small Molecule Therapeutics from 1998 to 2000. Dr. Fernandes was Vice President, Drug Discovery of Bristol-Myers Squibb Company from 1988 to 1998, Senior Director of Squibb Pharmaceutical Research Institute from 1987 to 1988, Senior Project Leader of Abbott Laboratories from 1983 to 1987 and Senior Microbiologist of the Squibb Institute for Medical Research, the research division of E.R. Squibb and Sons, from 1980 to 1983. She has served on the advisory board of Optimer Pharmaceuticals, Inc. since 2004 and the supervisory board of GPC Biotech AG from 2004 to 2008. Dr. Fernandes served on the product development working group for Biodefense for the National Institute of Allergy and Infectious Diseases from 2003 to 2004 and the U.S. Congressional Panel for Assessment of Impact of Antibiotic Resistant Bacteria and the American Society for Microbiology Advisory Panel for Antibiotic Resistance from 1991 to 1995. Dr. Fernandes holds a B.S. in botany, zoology and chemistry from the University of Bangalore (India), an M.S. in microbiology from the Christian Medical College (India) and a Ph.D. in microbiology from Thomas Jefferson University.

Mark Hahn

 Mr. Mark W. Hahn is Chief Financial Officer, Executive Vice President of Cempra Inc. Mr. Hahn has been Executive Vice President and Chief Financial Officer since February 2010. From 2008 to 2009, Mr. Hahn was the Chief Financial Officer of Athenix Corp., an agricultural biotechnology company, its merger with Bayer CropScience, where he served as Finance Director into 2010. Mr. Hahn has been the chief financial officer of various companies including GigaBeam Corporation, a telecommunications equipment company, from 2007 to 2008; BuildLinks, Inc., a software company, from 2002 to 2007; PerformaWorks, Inc., a software company, from 2001 to 2002; and Charles & Colvard, Ltd., a consumer products company, from 1996 to 2001. Mr. Hahn also served in various capacities, culminating in Senior Manager, at Ernst & Young and its predecessors from 1984 until 1996. Mr. Hahn holds a B.B.A. in accounting and finance from the University of Wisconsin-Milwaukee and is a certified public accountant in the State of Maryland.

David Gill

 Mr. David Gill is Director of Cempra, Inc. He joined INC Research, a clinical research organization, in February 2011 as Chief Financial Officer after having served as a board member and Audit Committee chairman from 2007 to 2010. He was previously the Chief Financial Officer of TransEnterix, a private medical device company from March 2009 to February 2011. Mr. Gill was Chief Financial Officer and Treasurer of NxStage Medical, Inc, a publicly-traded dialysis equipment company, from July 2005 to November 2006 at which time he retired to pursue several board of director opportunities, including LeMaitre Vascular (LMAT) and Isotis Biologics (ISOT).

Dov Goldstein

 Dr. Dov A. Goldstein, M.D., is an Independent Director of Cempra, Inc. He has been a partner at Aisling Capital since 2008. From 2006 to 2008, he was a Principal at Aisling Capital. From 2000 to 2005, Dr. Goldstein was Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals, Inc. (acquired by Pfizer Inc.). From 1998 to 2000, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures, a privately-held investment fund. Dr. Goldstein is a director of several privately held organizations including ADMA Biologics, Inc., Cardiokine, Inc., Durata Therapeutics, Inc., Esperion Therapeutics, Inc., Topaz Pharmaceuticals, Inc. and Scerene Healthcare, Inc. He holds a B.S. in biology from Stanford University, an M.D. from the Yale School of Medicine and an M.B.A. from the Columbia Business School.

John Johnson

 Mr. John H. Johnson is an Independent Director of Cempra, Inc. He has served as the Chief Executive Officer and as a director of Savient Pharmaceuticals, Inc. since 2011. Mr. Johnson was Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, Eli Lilly’s oncology business unit, from 2009 to 2011. From 2007 to 2009, Mr. Johnson was Chief Executive Officer of ImClone Systems Incorporated and was also a member of ImClone’s board of directors until it became a wholly-owned subsidiary of Eli Lilly in 2008. From 2001 to 2007, Mr. Johnson served as company group chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit. Mr. Johnson holds a B.S. in Education from East Stroudsburg University of Pennsylvania.

Richard Kent

 Dr. Richard S. Kent, M.D., is an Independent Director of Cempra, Inc. Beginning in 2010, Dr. Kent became a full partner at Intersouth Partners, a venture capital firm. He was a venture partner at Intersouth Partners from 2008 to 2010. From 2002 to 2008, Dr. Kent was the President and Chief Executive Officer of Serenex, Inc., a drug development company, when it was acquired by Pfizer Inc. From 2001 until he joined Serenex, Dr. Kent was President and Chief Executive Officer of Ardent Pharmaceuticals, Inc. Before that, he held senior executive positions at GlaxoSmithKline plc., where he was Senior Vice President of Global Medical Affairs and Chief Medical Officer, at Glaxo Wellcome plc., where he was Vice President of U.S. Medical Affairs and Group Medical Director, and at Burroughs Wellcome plc., where he was International Director of Medical Research. Dr. Kent currently serves as a director of Aldagen, Inc., a biopharmaceutical company, and served as a director of Inspire Pharmaceuticals, Inc. from 2004 to 2011. Dr. Kent holds a B.A. from the University of California, Berkley and an M.D. from the University of California, San Diego.

P. Sherrill Neff

 Mr. P. Sherrill Neff is an Independent Director of Cempra, Inc. Mr. Neff founded Quaker Partners Management, L.P. in 2002 and has since served as a partner at the investment firm. From 1994 to 2002, Mr. Neff was President and Chief Operating Officer of Neose Technologies, Inc., a biopharmaceutical company, and a director from 1994 to 2003. From 1993 to 1994, he was Senior Vice President, Corporate Development at U.S. Healthcare. Prior to that time, Mr. Neff was managing director at investment bank Alex Brown & Sons from 1984 to 1993 and a corporate attorney at Morgan, Lewis & Bockius from 1980 to 1984. Mr. Neff holds a B.A. from Wesleyan University and a J.D. from the University of Michigan Law School. Mr. Neff serves on the board of directors of Resource Capital Corporation, as well as several privately-held organizations including Biolex Therapeutics, Inc., Neuronetics, Inc., Optherion, Inc., RainDance Technologies, Inc. and Regado Biosciences, Inc. Mr. Neff also served on the board of directors of Amicus Therapeutics, Inc. from 1996 until 2011.

Basic Compensation

Name Fiscal Year Total

Garheng Kong

 --

Prabhavathi Fernandes

 1,335,990

Mark Hahn

 516,373

David Gill

 --

Dov Goldstein

 --

John Johnson

 --

Richard Kent

 --

P. Sherrill Neff

 --
As Of 30 Dec 2012

Options Compensation

Name Options Value

Garheng Kong

 0 0

Prabhavathi Fernandes

 0 0

Mark Hahn

 0 0

David Gill

 0 0

Dov Goldstein

 0 0

John Johnson

 0 0

Richard Kent

 0 0

P. Sherrill Neff

 0 0

Insider Trading

Name Shares Traded Price

MORRIS WISTAR I III

 2,500 $7.62

INTERSOUTH ASSOCIATES VI L L C

 732,989 $6.00

NEFF P SHERRILL

 1,189,805 $6.00

INTERSOUTH ASSOCIATES VI L L C

 488,659 $6.00

GOLDSTEIN DOV A

 1,213,663 $6.00

AISLING CAPITAL II L P

 1,213,663 $6.00

AISLING CAPITAL II L P

 1,213,663 $6.00

AISLING CAPITAL II L P

 1,213,663 $6.00
» Full list on Insider Trading
Search Stocks